SCORTEN and impaired renal function related to mortality of toxic epidermal necrolysis syndrome patients in the Asian population

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 5, 2013, Pages 628-633

  Hu, C H ^a   Chang, N J ^a   Liu, E K W ^a   Chuang, S S ^a   Chung, W H ^a   Yang, J Y ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMINOPENICILLIN; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; BICARBONATE; CARBAMAZEPINE; CEFTRIAXONE; CHINESE DRUG; COTRIMOXAZOLE; CREATININE; DICLOFENAC; ERYTHROMYCIN; GLUCOSE; IBUPROFEN; MEFENAMIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; TUBERCULOSTATIC AGENT; UREA; VANCOMYCIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; ASIAN; BICARBONATE BLOOD LEVEL; BODY SURFACE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GROUPS BY AGE; HERPES SIMPLEX VIRUS; HUMAN; IDIOPATHIC DISEASE; INFECTION; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RECORD REVIEW; MORTALITY; MYCOPLASMA; OUTCOME ASSESSMENT; POLYPHARMACY; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PULSE RATE; SCORING SYSTEM; SCORTEN SCORE; SURVIVAL PREDICTION; SURVIVOR; TAIWAN; TOXIC EPIDERMAL NECROLYSIS; UREA BLOOD LEVEL;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; HUMANS; KIDNEY; MEDICAL AUDIT; MIDDLE AGED; RETROSPECTIVE STUDIES; STEVENS-JOHNSON SYNDROME;

EID: 84876102602     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04502.x     Document Type: Article

References (25)

1. Palmieri TL, Greenhalgh DG, Saffle JR, et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil 2002; 23: 87-96.
2. Auquier-Dunant A, Mockenhaupt M, Naldi L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002; 138: 1019-1024.
3. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC,. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129: 92-96.
4. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600-1607.
5. Lyell A,. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956; 68: 355-361.
6. Roujeau JC, Guillaume JC, Fabre JP, Penso D, Flechet ML, Girre JP,. Toxic epidermal necrolysis (Lyell syndrome) incidence and drug etiology in France, 1981-1985. Arch Dermatol 1990; 126: 37-42.
7. Schopf E, Stuhmer A, Rzany B, Victor N, Zentgraf R, Kapp JF,. Toxic epidermal necrolysis and Stevens-Johnson syndrome an epidemiologic study from West Germany. Arch Dermatol 1991; 127: 839-842.
8. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P,. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149-153.
9. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P,. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204-212.
10. Prins C, Kerdel FA, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003; 139: 26-32.
11. Bradley T, Brown RE, Kucan JO, Smoot EC 3rd, Hussmann J,. Toxic epidermal necrolysis: a review and report of the successful use of Biobrane for early wound coverage. Ann Plast Surg 1995; 35: 124-132.
12. Khoo AK, Foo CL,. Toxic epidermal necrolysis in a burns centre: a 6-year review. Burns 1996; 22: 275-278.
13. Yamane Y, Aihara M, Ikezawa Z,. Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006. Allergol Int 2007; 56: 419-425.
14. Ying S, Ho W, Chan HH,. Toxic epidermal necrolysis: 10 years experience of a burns centre in Hong Kong. Burns 2001; 27: 372-375.
15. Cartotto R, Mayich M, Nickerson D, Gomez M,. SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center. J Burn Care Res 2008; 29: 141-146.
16. Trent JT, Kirsner RS, Romanelli P, Kerdel FA,. Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States. Arch Dermatol 2004; 140: 890-892.
17. Kim KJ, Lee DP, Suh HS, et al. Toxic epidermal necrolysis: analysis of clinical course and SCORTEN-based comparison of mortality rate and treatment modalities in Korean patients. Acta Derm Venereol 2005; 85: 497-502.
18. Trent JT, Kirsner RS, Romanelli P, Kerdel FA,. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami experience. Arch Dermatol 2003; 139: 39-43.
19. Vaishampayan SS, Das AL, Verma R,. SCORTEN: does it need modification? Indian J Dermatol Venereol Leprol 2008; 74: 35-37.
20. Guegan S, Bastuji-Garin S, Poszepczynska-Guigne E, Roujeau J-C, Revuz J,. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 2006; 126: 272-276.
21. Gravante G, Esposito G, Delogu D, Montone A, Sconocchia G,. More than two different bacterial species isolated from blood of toxic epidermal necrolysis patients significantly increase mortality. Burns 2006; 32: 793-794.
22. Hung C-C, Liu W-C, Kuo M-C, Lee C-H, Hwang S-J, Chen H-C,. Acute renal failure and its risk factors in Stevens-Johnson syndrome and toxic epidermal necrolysis. Am J Nephrol 2009; 29: 633-638.
23. Ducic I, Shalom A, Rising W, Nagamoto K, Munster AM,. Outcome of patients with toxic epidermal necrolysis syndrome revisited. Plast Reconstr Surg 2002; 110: 768-773.
24. Guh J-Y, Chen H-C, Tsai J-F, Chuang L-Y,. Herbal therapy is associated with the risk of CKD in adults not using analgesics in Taiwan. Am J Kidney Dis 2007; 49: 626-633.
25. Abood GJ, Nickoloff BJ, Gamelli RL,. Treatment strategies in toxic epidermal necrolysis syndrome: where are we at? J Burn Care Res 2008; 29: 269-276.